Kent Doi

• Opening Remarks
  Ravindra Mehta Speaker
• Opening Remarks
  Ji-Tseng Fang Speaker
• Organ Crosstalk in AKI
  Kent Doi Speaker Organ crosstalk in AKITargeted Polymyxin B Hemadsorption in Sepsis: Lessons from Japanese Experience and Patient Selection
• Kidney-Ventilator Interactions and Kidney Protective Ventilation /Lung and Kidney Crosstalk
  Kathleen Liu Speaker How do I Manage Patients with Combined Kidney and Liver FailureKidney-Ventilator Interactions and Kidney Protective Ventilation /or Lung and Kidney CrosstalkHow do I care for the Patient with ARDS and AKIDe-escalating and Transitioning RRT: Best Practices
• Hepatorenal Syndrome: Recognition and Management or Disordered Physiology or Latrogenic Failure
  Mitra Nadim Speaker Hepatorenal Syndrome: Recognition and Management or Disordered Physiology or Iatrogenic FailureManaging Patients With Combined Kidney and Liver FailureHow do I Manage Patients with Combined Kidney and Liver Failure
• Special Lecture: 50 years of CRRT: A Journey Through Innovation
  Claudio Ronco Speaker Hemoadsorption in the ICUSpecial lecture: 50 years of CRRT: a journey through innovationRole of Renal Functional Reserve on AKI risk and RecoveryHow do I use Hemadsorption in My PracticeManaging the Heart Failure Patient With Worsening Renal Function (WRF)
• Q & A

• Opening
• Targeted Polymyxin B Hemadsorption in Sepsis: Lessons from Japanese Experience and Patient Selection
  Kent Doi Speaker Organ crosstalk in AKITargeted Polymyxin B Hemadsorption in Sepsis: Lessons from Japanese Experience and Patient Selection
• From Guidelines to Bayesian Trials: How Should We Interpret Polymyxin B Hemoadsorption in Sepsis?
  Yen-Ta Huang Speaker From Guidelines to Bayesian Trials: How Should We Interpret Polymyxin B Hemoadsorption in Sepsis?Polymyxin B hemoadsorption has occupied an unusually contested place in sepsis care, and the way authoritative bodies describe it has shifted over time. This talk traces that evolution—from the 2020 Taiwan AKI consensus through the 2021 and 2026 Surviving Sepsis Campaign guidelines—and uses the changing recommendations as a lens on the methodological debates that underlie them. From an evidence-based medicine standpoint, the controversy is less about the device than about how we generate and grade evidence. I will first examine the frequentist evidence base, including our network meta-analysis of blood purification therapies for severe infection and sepsis/septic shock published in Critical Care Medicine. I will outline what a network meta-analysis adds—coherent ranking across multiple modalities, indirect comparison, and explicit quantification of heterogeneity—while being candid about its limitations, including reliance on the transitivity assumption, sparse networks, and the fragility of mortality estimates pooled from heterogeneous trials. I will then turn to the recently reported TIGRIS trial, which used a Bayesian, enrichment-based phase 3 design with prespecified borrowing from the EUPHRATES treatable cohort. I will highlight the strengths of the Bayesian presentation—direct posterior probabilities of benefit, transparent incorporation of prior evidence, and efficiency in a rare, mechanistically defined phenotype—alongside the cautions it demands: sensitivity to prior choice, the open-label design, and the gap between a high posterior probability and a confirmed effect. Bringing these strands together, the talk offers a multifaceted, methodology-driven reading of polymyxin B hemoadsorption in sepsis, and a transferable framework for clinicians facing the increasingly common situation in which guidelines, frequentist syntheses, and Bayesian trials appear to diverge.
• Q&A

• AKD Care Redefined: Diabetes, Hypertension, and Strategies for Long-Term Health
  VinCent Wu Speaker AKD Care Redefined: Diabetes, Hypertension, and Strategies for Long-Term Health
• Drug Exposures: Concerns in Kidney Safety (PPI vs Potassium-Competitive ACID Blockers (P-CABs))
  Kyungho Lee Speaker
• Acute PD vs Acute HD: Which Is the Right Choice? or Tropical Nephrology: Leptospirosis, Dengue, Malaria
  Nattachai Srisawat Speaker Precision Sepsis-AKI — Biomarkers, AI and Phenotyping in the Asia-PacificTiming of DialysisAcute PD vs Acute HD: Which Is the Right Choice?
• Tackling Heterogeneity: Phenotyping for Hemadsorption or Defining What Matters in AKI Trials: Heterogeneity and Future Direction of Major Adverse Kidney Events
  Kent Doi Speaker Organ crosstalk in AKITargeted Polymyxin B Hemadsorption in Sepsis: Lessons from Japanese Experience and Patient Selection
• Extracorporeal Therapies in Trauma, Burns and Cerebral Edema
  John Prowle Speaker Trajectories of Critical Illness – Defining Endotypes from Routine DataCritical illness is a heterogeneous syndrome characterized by diverse clinical trajectories and variable responses to treatment. Defining biologically and clinically meaningful endotypes using routinely collected healthcare data offers an opportunity to improve risk stratification, prognostication, and personalized therapeutic strategies, enabling earlier intervention, enhanced clinical decision-making, and precision medicine in critical care. In particular the transition from acute to persistent critical illness represents a pivotal phase in intensive care, marked by a shift from the initial disease insult to prolonged organ dysfunction driven by complex host responses. Early identification of patients at risk of this transition remains a major clinical challenge and opportunity.Dynamic Prescription of CRRT Ready for Prime TimeContinuous renal replacement therapy (CRRT) has evolved from a standardized supportive therapy to a platform for precision critical care. Increasing evidence suggests that fixed prescriptions fail to accommodate the dynamic physiological changes encountered during critical illness, resulting in suboptimal solute clearance, fluid management, and metabolic control. Dynamic prescription integrates evolving haemodynamic status, fluid balance, acid–base homeostasis, electrolyte disturbances, and recovery trajectories to optimize therapy delivery while minimizing complications and treatment interruptions. This paradigm supports individualized kidney support rather than protocol-driven care. Emerging decision-support systems and data-driven algorithms have the potential to transform CRRT into a responsive, patient-centred intervention, improving kidney recovery, organ support, and outcomes in critically ill patients. Adapting CRRT for patients with Electrolyte and acid-base disordersContinuous renal replacement therapy (CRRT) is uniquely positioned to provide precise correction of complex electrolyte and acid–base disturbances in critically ill patients. Beyond kidney support, modern CRRT prescriptions can be individualized to account for the severity and evolution of dysnatremia, dyskalemia, calcium disorders, and metabolic acidosis or alkalosis. Customization of dialysate and replacement fluid composition, treatment dose, buffer delivery, and regional citrate anticoagulation enables controlled correction while minimizing the risks of metabolic complications. Dynamic prescription based on serial biochemical monitoring and changing clinical physiology can be embedded into treatment protocols, facilitating safe correction of sodium, potassium, calcium, and bicarbonate abnormalities while optimizing organ support and improving outcomes in critically ill patients. Extracorporeal Therapies in Trauma, Burns and Cerebral OedemaExtracorporeal therapies (ECTs) are an important adjunct in the management of critically ill patients with severe trauma, major burns, and brain injuries. Acute kidney injury, systemic inflammation, rhabdomyolysis, and profound fluid and electrolyte disturbances frequently complicate these conditions, necessitating timely organ support. Continuous kidney replacement therapy (CKRT) provides effective management of metabolic derangements while enabling precise fluid balance in hemodynamically unstable patients. In trauma and burns, ECTs may facilitate the clearance of myoglobin in severe rhabdomyolysis, support fluid management during resuscitation, and could enable removal of damage or pathogen associated molecular patterns mediating multiorgan failure. In patients with cerebral edema, CKRT offers gradual osmotic control and minimizes intracranial pressure fluctuations compared with intermittent dialysis, making it the preferred modality when kidney replacement therapy is required. We will review current evidence, practical considerations, and emerging extracorporeal strategies, highlighting their role in improving physiological stability and supporting recovery in critically ill patients.
• Q & A